Britain investigates possible allergic reaction to COVID vaccine

Officials in the UK are advising citizens who have frequent allergic reactions not be vaccinated.


Written by ČTK Published on 11.12.2020 08:57:00 (updated on 11.12.2020) Reading time: 2 minutes

The British health authorities are investigating two cases of an adverse response to the coronavirus vaccine from Pfizer and BioNTech, which occurred on the day the mass vaccination program began. At the same time, they advised people who had experienced severe allergic reactions in the past not to be vaccinated with this vaccine, AP reported on Wednesday.

Stephen Powis, a spokesman for Britain's NHS health system, said the authorities were acting on the recommendations of the MHRA regulatory drug agency.

"As is common with new vaccines, the MHRA recommends that, as a precautionary measure, people with frequent allergic reactions should not be vaccinated," said Powis. He added that the decision follows two reported cases in which people with a history of severe allergic responses to the vaccine responded unfavorably. "They're both recovering."

Two cases of possible allergic reaction occurred on Tuesday, which was the inaugural day of the mass vaccine program against COVID-19 in Britain. MHRA chief June Raine told MEPs that the allergic reactions reported were not a side effect observed during clinical trials.

The European Medicines Agency (EMA) has stated that they cannot guarantee at this stage that it will recommend the COVID-19 vaccine from the American company Pfizer and its German partner BioNTech for approval, head of the agency Emer Cooke, told Reuters yesterday.

Pfizer, BioNTech and the American company Moderna applied for conditional registration of their vaccines on the European Union market in early December. The EMA is currently researching vaccines, and will evaluate the Pfizer and BioNTech versions by Dec. 29 and Moderna by Jan. 12. The decision must then be approved by the European Commission.

"We have a dataset of more than 30,000 subjects monitored during clinical trials. This gives us a very strong set of safety and efficacy data on which to base our decisions," Cooke told MEPs. "We cannot guarantee that the (evaluation) will have a positive result," she added.

The Czech government plans to buy vaccines for about 5.5 million people, who may be vaccinated by late summer, 2021. The Czech Republic has a population of 10.7 million. People suffering from chronic diseases, the elderly, health personnel and workers in the critical state infrastructure should be given priority in the vaccine distribution.

Would you like us to write about your business? Find out more